If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Oral Immunostimulating Therapy Reduces Severity, Duration of Paediatric Respiratory Infections: Presented at ESPID By Jenny Powers NICE, France -- May 12, 2010 -- Children who are prone to upper respiratory tract infections may be able to experience fewer infections or reduce the severity and duration of infections if treated with oral immunostimulating therapy (OM-85). Results were presented here May 7 at the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Oral immunostimulating therapy is the product of alkaline proteolysis from lysates of following bacteria: Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, and Moraxella catarrhalis. Urs B. Schaad, MD, Division of Pediatric Infectious Diseases, University Children's Hospital, Basel, Switzerland, and colleagues randomised 396 children aged 2 to 6 years to receive oral immunostimulating therapy (1 capsule per day) for 1 month and then again during the first 10 days of months 3, 4, and 5 or a placebo. All of the children had experienced >=4 upper respiratory tract infections during the previous year. The mean rate of upper respiratory tract infections during the 150-day treatment period was significantly lower in children receiving immunostimulating therapy, compared with those receiving placebo (1.97 vs 2.42; P = .0016). When respiratory infections did occur, children receiving immunostimulating therapy had less severe infections than children on placebo (P = .0029), as well as a mean shorter duration of illness (P = .0002). In addition, children who received oral immunostimulating therapy required less additional antibiotic therapy (P < .0001). More adverse events were observed in the placebo group than in the group receiving immunostimulating therapy. [Presentation title: Double-Blind, Placebo-Controlled, Randomised Multicenter Study of OM-85 (Broncho-Vaxom), an Immunostimulant, in Paediatric Recurrent Upper Respiratory Tract Infections. Abstract 577]
|
